Cargando…
Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL(pro) through high-throughput virtual screening and molecular dynamics simulation
It has been confirmed that the new coronavirus SARS-CoV-2 caused the global pandemic of coronavirus disease 2019 (COVID-19). Studies have found that 3-chymotrypsin-like protease (3CL(pro)) is an essential enzyme for virus replication, and could be used as a potential target to inhibit SARS-CoV-2. In...
Autores principales: | Liu, Wen-Shan, Li, Han-Gao, Ding, Chuan-Hua, Zhang, Hai-Xia, Wang, Rui-Rui, Li, Jia-Qiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993695/ https://www.ncbi.nlm.nih.gov/pubmed/33678621 http://dx.doi.org/10.18632/aging.202703 |
Ejemplares similares
-
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020) -
Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021) -
Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023) -
Virtual Screening of FDA-Approved Drugs for Enhanced Binding with Mitochondrial Aldehyde Dehydrogenase
por: Zhou, Boqian, et al.
Publicado: (2022) -
Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: a high throughput virtual screening study
por: Srivastava, Varshita, et al.
Publicado: (2023)